Archives for December 2011

Pertuzumab Update: The New Kid on “HER” Block

  Although trastuzumab has led to significant improvements in treating HER2-positive breast cancers, many patients relapse and develop resistance to trastuzumab. The HER family of growth factor receptors consists of four closely related… [Learn More…]

Zoledronic Acid Update

Adjuvant therapy with non-nitrogenous bisphosphonates has not been shown to improve progression free survival (PFS) and overall survival (OS) in estrogen positive breast cancer patients. A clinical trial meta analysis of adjuvant clodronate… [Learn More…]

Pertuzumab: The New Kid on “HER” Block

Approximately 20% of all breast cancers are caused by the oncogenic human epidermal growth factor receptor 2 (HER2) and although trastuzumab has led to significant improvements in treating HER2-positive breast cancers, many patients develop… [Learn More…]

S-1: A Synergistic Drug Combination that Improves Overall Survival in Patients with Stage II and III Gastric Cancer

S-1 (TS-1) is a chemotherapeutic preparation combining tegafur, gimeracil and oteracil potassium in a molar ratio of 1:0.4:1 that significantly improves overall survival in patients with stage II or III gastric cancer. In this study, patients that… [Learn More…]